Novo Nordisk

  • A Pharmacology Primer for the Biotech Investor

    By Seth Robey - August 16, 2013 | Tickers: LLY, MNKD, NVO, RHHBY

    In Pharmacology we don't only have to consider the actions of the drug on the body.  It is also important to understand the way the body processes the drug, or the Pharmacokinetics.  When you consider that drugs, like the nutrients in food, must be absorbed (A), distributed (D) throughout the body, metabolized (M), and excreted/eliminated (E), pharmacokinetics becomes a critical consideration in drug development.  Investors with a keen more »

  • A Key Healthcare Technology Worth Millions

    By Kanak Kanti - August 16, 2013 | Tickers: CBST, NKTR, NVO

    Nektar Therapeutics (NASDAQ: NKTR) has an interesting business model. It developed a key technology that bridges a crucial shortcoming of another very useful technology, broadening its scope in the kinds of drugs it can be used to manufacture. Nektar licenses this technology to some of the largest biotech companies, helping create some of their top blockbuster drugs. It makes millions of dollars every time another company’s drug in development more »

  • A Closer Look at 3 Players in Diabetes Treatments

    By Leo Sun - August 16, 2013 | Tickers: MNKD, NVO, OSIR

    Two niche players in diabetes treatments -- Osiris Therapeutics (NASDAQ: OSIR) and MannKind (NASDAQ: MNKD) -- rallied strongly recently, after the two companies announced positive study results regarding their flagship products. Osiris, which uses stem cell treatments for bone and skin grafts, and MannKind, which is the last major company dedicated to producing inhalable insulin, are closely watched by biotech investors since an FDA approval would grant both companies instant monopolies in more »

  • A Fine Act of balancing by Sanofi

    By Shalini Agrawal - July 27, 2013 | Tickers: LLY, MRK, NVO, SNY

     

    In the history spanning more than two centuries, Sanofi (NYSE: SNY) has undergone number of major and minor changes to reach the level of integrated healthcare leader as it is today. To achieve this, Sanofi has been quick to spot the value-enhancing growth opportunities resulting in a number of mergers and acquisitions that the company has undertaken successfully.

    The company’s product lie into 3 major segments termed as Pharmaceuticals more »

  • Longer But Less Healthy Lives Will Benefit This Trio

    By Reuben Brewer - July 25, 2013 | Tickers: NVO, NTRI, UHS

    NutriSystem (NASDAQ: NTRI), Novo Nordisk (NYSE: NVO), and Universal Health Services (NYSE: UHS) should all benefit as Americans live longer, but face more illnesses than they did a decade ago.

    Researchers from the University of Washington and the US Burden of Disease project reviewed health records from multiple countries to compare the health of citizens from nations around the world. One outcome from the work was the already well-known conclusion more »

  • Billionaire Ken Fisher’s Healthcare Picks for Q3

    By Meena Krishnamsetty - July 21, 2013 | Tickers: GSK, JNJ, NVO, PFE, SNY

    In mid July, Fisher Asset Management, the asset management firm run by billionaire and Forbes columnist Ken Fisher, filed its 13F for the second quarter of 2013 with the SEC, disclosing many of its long equity positions as of the end of June. Insider Monkey tracks these filings in our database, using them to help us develop investment strategies (for example, we have found that the most popular small cap more »

  • The Future of Sanofi's Insulin Empire

    By Brandy Betz - July 17, 2013 | Tickers: LLY, NVO, SNY

    Sanofi (NYSE: SNY) appeared at the American Diabetes Association meeting last month, touting data for the new insulin U300 and a combo therapy involving its approved drugs Lyxumia and Lantus. Could these new drugs keep Sanofi near the top of the diabetes market heap?

    Lantus is Sanofi’s top-selling product, earning 5 billion euros (or about $6.5 billion at current exchange rates) in sales last year. But the drug more »

  • Could This Safe Play Help Eli Lilly?

    By Brandy Betz - July 11, 2013 | Tickers: BMY, LLY, GSK, NVO, SNY

    Note: This version has been amended to better reflect Victoza's dosage recommendations.

    At the American Diabetes Association meeting last month, Eli Lilly (NYSE: LLY) presented promising data for the GLP-1 agonist dulaglutide. GLP-1s are a well-established diabetes drug class dominated by Novo Nordisk (NYSE: NVO) and Bristol-Myers Squibb (NYSE: BMY).

    GLP-1 agonists are typically used as a second-line combo therapy for type 2 diabetes patients not responding to metformin more »

  • How Paula Deen's Mishap May Impact the Market

    By Stephanie Faris - July 2, 2013 | Tickers: NVO, SNI, SFD

    However you feel about celebrity chef Paula Deen, it's hard to ignore the impact one person has on the business world. As major brands lined up to pull the plug on deals with Deen, many consumers wondered if it's already too late. Brands like Wal-Mart and Walgreen, which merely carried the chef's products, will likely be unfazed, but what about those brands that had closer associations?

    In more »

  • Is This What the Doctor Ordered for Eli Lilly?

    By Kanak Kanti - June 27, 2013 | Tickers: BMY, LLY, JNJ, MRK, NVO

    After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly (NYSE: LLY) finally has some good news to report. Releasing top-line results for its type II diabetes experimental drug dulaglutide, the company announced that patients taking the drug had manageable side effects, showed better blood sugar control, and lost more weight compared to existing drugs.

    If Lilly gains FDA approval for dulaglutide more »

  • Can Investors Bet on These 3 Pharma Companies?

    By Madhukar Dubey - June 27, 2013 | Tickers: JNJ, NVS, NVO, SNY

    According to the World Health Organization, there are 347 million people around the world who suffer from diabetes.

    It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide. As such, the overall market for diabetes therapies and diagnostics is estimated to increase from $38 billion in 2010 to $53 billion in 2015. Because more »

  • Tme to Buy This Defensive Growth Stock?

    By Lee Samaha - June 11, 2013 | Tickers: JNJ, NVO, COO, VRX

    Everyone loves a defensive growth story, and there aren’t many better companies in the category than Cooper Companies (NYSE: COO). In general, ophthalmology is an industry that can grow irrespective of the economy. Within this, Cooper has its own mix of earnings drivers with which it can generate superior industry growth.

    It is a compelling mix. In fact, so much so that the stock has gotten away from this more »

  • Should These Drug Companies Continue to Pay a Dividend?

    By Chris Hodge - May 24, 2013 | Tickers: AGN, RDY, NVO

    Editor's Note: The article has been modified to better describe the current companies' dividend arrangements.

    Even a hardcore dividend addict such as I will admit that there are times when a company should hold off on paying a dividend. The following is an examination of a few companies in the drug manufacturing sector and my conclusions about their dividend arrangements. In short, should these companies continue to pay dividends more »

  • A New Drug Sales Model

    By Reuben Brewer - May 20, 2013 | Tickers: NVO, PFE, TEVA | Editor's Choice

    Pfizer (NYSE: PFE) is trying a new sales paradigm, selling direct to patients. If this effort works, it could completely change the pharmaceutical industry.

    Little blue pills

    One of Pfizer's best selling drugs is Viagra, which is used to treat erectile dysfunction. That particular ailment carries material social stigma and the pills, which are still under patent protection for many more years, can be expensive. That has proven to more »

  • Good News For Health Care Stocks

    By Reuben Brewer - May 17, 2013 | Tickers: CAH, CVS, NVO

    New research shows that Medicaid coverage leads to an increased use of health care services. That's not surprising, but it does have big implications for health care stocks.

    The Oregon Study

    The New England Journal of Medicine recently released the results of an important study. The Oregon Study, as it's called, tracked that state's test of randomly assigning lower-income adults into two groups, one that received Medicaid more »

  • Does the Healthcare Industry mean Stability?

    By tarun bachhawat - May 14, 2013 | Tickers: BDX, COV, NVO

    A leading medical technology company, Becton, Dickinson and Company's (NYSE: BDX) earnings were better than expected. It is one of the few medical companies that is able to deliver organic growth in a challenged healthcare industry. 

    A decent quarter
     
    Becton Dickinson reported revenue of $2 billion for the quarter and profit of $275.6 million, beating Wall Street's estimate by $0.04 per share. Revenue from sales in more »
  • Will Obesity Drugs Gain Soon?

    By Brandy Betz - May 14, 2013 | Tickers: ARNA, NVO, OREX, VVUS

    Things are beginning to look slightly up for obesity drugmaker Vivus (NASDAQ: VVUS) -- mere weeks before a competing drug from Arena (NASDAQ: ARNA) hits the market.

    Vivus shares soared nearly 10% last Wednesday despite lackluster first quarter results. That’s because CEO Leland Wilson expressed an interest in finding a big pharma partner for the faltering Qsymia, which had a meager sales of $4.1 million in the quarter and more »

  • Why This Stock's Crash is a Buying Opportunity

    By Lee Samaha - May 13, 2013 | Tickers: AGN, NVO, REGN, VRX

    It’s been a varied reporting season with a general uptrend in markets accompanying more than a few profit warnings. If you’ve been holding some of these names before the disappointments then it has been painful. The good news is that these situations can create buying opportunities. I think Allergan (NYSE: AGN) is a case in point, and here is why.

    Allergan’s Outlook

    It was almost a tale more »

  • The Ups and Downs of Diabetes

    By Tyler Wofford - May 8, 2013 | Tickers: ABT, MRK, NVO

    Recently, I have focused in on some companies that play a major role in diabetic's lives like mine. The financial implications of this disease are astounding, and have presented what seems to be a great opportunity for investors. Today, I will discuss the earnings results of some of the largest players involved with the disease. 

    Let's get the biggest surprise (to me) out of the way. I have more »

  • One Soda a Day Keeps Your Health Away

    By Tyler Wofford - May 2, 2013 | Tickers: KO, NVO, PEP

    Medscape is reporting the results of studies showing how just one soda each day can increase a person's chance of developing type 2 diabetes by as much as 25%. While this isn't necessarily surprising, the American Heart Association recommends not drinking more than 450 calories a week of sugar-sweetened beverages.

    That's three 12-ounce cans of PepsiCo (NYSE: PEP)Let's look at these soda companies and maybe more »

  • Page 1 of 3